BioLight Life Sciences Ltd.
BOLT
Rank in Stocks
#29314
BioLight Life Sciences Ltd. is an ophthalmic firm dedicated to discovering,... BioLight Life Sciences Ltd. is an ophthalmic firm dedicated to discovering, developing, and bringing to market innovative products and pipeline candidates designed to tackle various eye-related ailments. Its portfolio and development pipeline include DiagnosTear's TeaRx, a diagnostic platform analyzing tear fluid components to identify frontal eye diseases, and Peripherex, offering solutions for both at-home and clinical diagnosis and monitoring of peripheral vision loss, crucial for conditions like glaucoma. For glaucoma, BioLight features ViSci (an Eye D technology utilizing a subconjunctival implant), Belkin Vision's rapid, automated laser system for effective intraocular pressure reduction, and Sanoculis, which is advancing a novel surgical approach. The company also encompasses OphRx, focused on developing pharmaceutical treatments for ocular disorders; AEYE, which designs artificial intelligence-powered solutions for diverse retinal conditions; and Tarsier, working on TRS 01, a platform-based treatment for uveitis in patients with elevated intraocular pressure. Founded in 2005, the Tel Aviv, Israel-based company operated as Bio Light Israeli Life Sciences Investments Ltd. until its rebranding to BioLight Life Sciences Ltd. in February 2016.
Share Price
$0.91269126
Last synced: 2026-11-09
Market Cap
$8.26M
Change (1 day)
1.67%
Change (1 year)
-27.06%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade BioLight Life Sciences Ltd. (BOLT)
Category
Healthcare
EPS for BioLight Life Sciences Ltd. (BOLT)
EPS as of June 2026 TTM: $-0.43
According to BioLight Life Sciences Ltd.'s latest financial reports, its current EPS (TTM) is $-0.43. At the end of 2025 the company had an EPS of $-0.62, a decrease compared to its 2024 EPS of $-0.42.
EPS history for BioLight Life Sciences Ltd. from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.43 | -30.79% |
| 2025 | $-0.62 | 48.39% |
| 2024 | $-0.42 | -73.06% |
| 2023 | $-1.55 | 218.85% |
| 2022 | $-0.49 | -1,905.56% |
| 2021 | $0.03 | -102.94% |
| 2020 | $-0.92 | 14.48% |
| 2019 | $-0.80 | -119.40% |
| 2018 | $4.13 | -368.40% |
| 2017 | $-1.54 | -26.74% |
| 2016 | $-2.10 | 6.13% |
| 2015 | $-1.98 | -35.43% |
| 2014 | $-3.07 | -22.58% |
| 2013 | $-3.96 | -7.47% |
| 2012 | $-4.28 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $8.45 | -2,069.24% |
IE
|
|
| $0.21 | -148.59% |
CN
|
|
| $19.69 | -4,688.39% |
CH
|
|
| $4.34 | -1,110.95% |
CH
|
|
| $0.13 | -129.36% |
CN
|
Questions about BioLight Life Sciences Ltd.'s earnings per share (EPS)
What is BioLight Life Sciences Ltd.'s earnings per share (EPS)?
BioLight Life Sciences Ltd.'s earnings per share (EPS) over the last twelve months is $-0.43, as of Jun 2026.
What was BioLight Life Sciences Ltd.'s earnings per share (EPS) in 2025?
In 2025, BioLight Life Sciences Ltd.'s earnings per share (EPS) was $-0.62, compared with $-0.42 in 2024.
How has BioLight Life Sciences Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, BioLight Life Sciences Ltd.'s earnings per share (EPS) was highest in 2021 ($0.03) and lowest in 2023 ($-1.55).
How does BioLight Life Sciences Ltd.'s earnings per share (EPS) compare with similar companies?
BioLight Life Sciences Ltd.'s earnings per share (EPS) ($-0.43) is lower than that of all 5 similar companies listed above. The highest among them is Ypsomed Holding AG, with $19.69.